Ondansetron - ADial Pharmaceuticals

Drug Profile

Ondansetron - ADial Pharmaceuticals

Alternative Names: AD-04

Latest Information Update: 14 Dec 2015

Price : $50

At a glance

  • Originator ADial Pharmaceuticals
  • Class Antiemetics; Antipsychotics; Carbazoles; Imidazoles; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Alcoholism
  • Phase I Obesity; Opioid abuse; Smoking withdrawal

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 14 Dec 2015 Clinical development is ongoing in USA
  • 24 Apr 2013 ADial Pharmaceuticals plans two phase III trials for Alcoholism in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top